Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
8,706 total articles
Cheniere (LNG) looks like a favorable mid-term long trade: fundamental cash flow strength, an export supply shock supporting U.S. LNG pricing, and visible project ramp catalysts support upside toward the $300 area. Balance the trade with a defined stop below $244 given leverage and event risk.
Peabody Energy (BTU) is a cheap, cash-generating coal producer positioned to benefit from tighter LNG markets and rising Asian coal demand. Balance a position: entry at $24.95, tight stop at $21.50, target $32.00 over a mid-term swing. Reasons to be constructive include a low EV/sales multiple, modest leverage, dividend resumption, and operational …
Clean Harbors has pulled back into the mid-$200s after hitting a 52-week high of $316.98. The pullback is a tactical buying opportunity for investors focused on durable growth, steady free cash flow, and an industry benefit from stricter waste regulations and recycling expansion. This trade idea lays out an entry, stop, targets, and the reasoning b…
Rockwell Automation posted better-than-expected Q2 results and raised full-year guidance, validating accelerating demand across warehouse automation, semiconductors, data centers and energy. The company pairs recurring software and services revenue with cyclical hardware exposure - a mix that benefits from Industry 4.0 spending. This trade idea set…
PagerDuty ($PD) is trading near multi-month lows with a market cap ~ $582M, positive free cash flow and a freshly reported 25% adjusted operating margin. Technicals show bullish momentum and short interest remains meaningful. This trade idea lays out a mid-term (45 trading days) long with concrete entry, stop and target levels while flagging cataly…
Bausch Health (BHC) is trading at bargain equity values relative to its free cash flow, but the company's heavy leverage and low trading volumes make the equity a binary play that requires visible progress on deleveraging to unlock meaningful upside.
Argan (AGX) is trading at a premium, but a near-$3 billion backlog, clean balance sheet and strong Q4 profitability create a repeatable growth lane tied to AI and data-center power demand. This trade idea outlines a long entry, clear stops and targets, and the thesis drivers and risks to watch over a 180-trading-day horizon.
Hecla Mining (HL) has bounced off the March lows but recent momentum is weak, volume profile shows heavy selling and technicals point to stalled upside. With a market cap north of $12B, thin margins to metal prices, and elevated valuation multiples relative to cash flow, we see a short opportunity for a short-term trade aimed at a $15 target over r…
Celestica is an overlooked beneficiary of the AI hardware build-out. Strong Q1 results, a raised $19B revenue guide and a strategic AMD partnership point to continued revenue and margin expansion. The stock’s post-earnings drop looks like an emotional reaction, creating a measured long entry with defined risk controls.
Palantir just delivered an 85% year-over-year revenue quarter and raised guidance, yet the stock sold off on valuation worries. At $134.65 and a market cap near $320B, the setup looks like a tradeable long: durable government cashflows, accelerating U.S. commercial revenue, and strong free cash flow. The trade works only if growth remains elevated;…
Micron's business is squarely in the middle of an AI-driven memory supercycle. With free cash flow of roughly $10.3B, a clean balance sheet (debt/equity ~0.14) and unit economics that have improved dramatically, I see a credible path for MU to exceed $1,500 within the next 180 trading days if AI demand continues and supply remains disciplined. This…
DoorDash is trading well below its 52-week high but showing clear signs of durable revenue expansion and margin improvement. With $2.17B in free cash flow, manageable leverage and a market cap near $73B, the stock offers a tactical swing opportunity as fundamentals and technicals align for a mid-term rally. This trade idea lays out a clear entry, s…
Energy Transfer (ET) is a capital-intense midstream operator with the footprint and contracts to benefit if AI and data-center expansion drive sustained power demand. This trade idea outlines a long position with a clear entry, stop, and target, plus catalysts and risks that matter to traders over a 180-trading-day horizon.
Occidental (OXY) is trading well below its 52-week high after a big rebound earlier in 2026. With free cash flow of roughly $4.1B, a manageable debt-to-equity ratio near 0.62, and oil prices still elevated, a confirmed CEO transition that prioritizes buybacks and capital returns could re-rate the stock. This trade idea proposes a mid-term long with…
Klaviyo has been hammered in recent sessions, trading down to $15.81 after a rush of short activity and panic selling. The core business - a data-driven ecommerce marketing platform with strong free cash flow and healthy liquidity - still argues for upside. This is a swing trade: buy the panic, size it appropriately, and manage risk with a strict s…
PayPal is trading at roughly 9x earnings and generating over $5.5B in free cash flow while the market focuses on near-term margin pain and competition. That pessimism looks priced in. This trade idea lays out a mid-term swing long with entry, stop and target, plus catalysts and risks to monitor.
Meta is pulling back from recent highs, but fundamentals still support owning the stock. Strong free cash flow ($48.25B), healthy ROE (29%), and a reasonable P/E (~22x) coupled with continued ad and data-center-driven AI demand make a mid-term long trade attractive. Enter near $610 with a tight stop and a two-stage target plan tied to a recovery in…
PayPal is trading at a compelling multiple after a difficult run; the company still generates strong free cash flow, benefits from Venmo and BNPL tailwinds, and trades below previous valuation highs. We lay out a mid-term trade: enter on weakness, cap risk with a clear stop, and target a recovery toward healthier multiples if fundamentals reacceler…
Neurocrine (NBIX) is a high-quality cash-flowing biotech with a $14.8B market cap, durable Ingrezza royalties and a growing pipeline. The April Soleno deal introduces a binary upside via Vykat XR but adds near-term execution and integration risk. We favor a tactical long over the next 45 trading days with a clear entry, stop and target.
Blue Owl (OWL) is trading well below intrinsic cash-flow metrics while still paying an ~8% yield. Redemption noise and private credit headlines have pushed the stock into bargain territory. This trade buys the fear, uses a tight stop, and targets a recovery driven by cash flow stability, dividend support, and a re-rating if redemption pressures pro…
PayPal is trading well below prior highs but still generates strong free cash flow and benefits from faster-growing Venmo and BNPL volumes. Valuation looks attractive on P/E, EV/EBITDA and free-cash-flow metrics. This trade idea favors a measured long with a defined entry, stop and target over a 180-trading-day horizon while acknowledging execution…
Liberty Global (LBTYA) trades cheaply on headline multiples ($12.29) with a $4.24B market cap and an EV of ~$10.65B. Recent AI partnership, Liberty Blume progress, and ongoing asset moves create a realistic path to a re-rate. This trade sets a clear entry at $12.30, a stop at $10.50, and a mid-term target of $15.00 (45 trading days) to capture near…
Mobileye's Q1 picture is mixed on headline GAAP noise but strengthened by China OEM demand, a $250M buyback and durable ADAS traction. The trade is a tactical long into mid-term catalysts with a clear stop to limit downside if legacy concerns re-emerge.
Jazz Pharmaceuticals' positive Phase 3 Ziihera results have transformed its growth trajectory. The market has reacted, but Jazz still offers a compelling risk/reward: $14.6B market cap, $1.297B free cash flow and an EV/EBITDA of 13.7 imply room for multiple expansion if commercial rollouts and approvals proceed. This trade recommends a long with cl…
BioMarin (BMRN) is a Strong Buy on a concrete catalyst set: expanding demand for VOXZOGO in skeletal dysplasia and a value-accretive acquisition of Amicus. The balance sheet, free cash flow and a modest valuation frame a favorable risk/reward. Trade plan: enter $54.60, target $68.00, stop $49.00, horizon mid term (45 trading days).
